- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06934226
En studie for å vurdere effekt og sikkerhet for JNJ-77242113 sammenlignet med placebo og ustekinumab hos deltakere med moderat til alvorlig plakk-psoriasis (ICONIC-ASCEND)
En fase 3 multisenter, randomisert, dobbeltblind, placebokontrollert og ustekinumab aktiv komparatorstyrt studie for å evaluere effektiviteten og sikkerheten til JNJ-77242113 for behandling av deltakere med moderat til alvorlig plakk-psoriasis
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
Studieoversikt
Status
Forhold
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Barrio Gral Paz Cba Capital, Argentina, X5000
- Consultora Integral de Salud SRL
-
Buenos Aires, Argentina, B1643CRO
- Instituto Medico De Alta Complejidad (IMAC)
-
Buenos Aires, Argentina, C1417EYG
- Mindout Research
-
Buenos Aires, Argentina, C1425
- Instituto de Neumonologia y Dermatologia
-
CABA, Argentina, C1061AAS
- CIPREC
-
CABA, Argentina, C1199ABB
- Hospital Italiano de Buenos Aires
-
CABA, Argentina, C1055AAO
- Buenos Aires Skin
-
CABA, Argentina, C1056ABH
- Investigaciones Medicas IMOBA SRL
-
CABA, Argentina, C1128
- Mautalen Salud e Investigacion
-
Caba, Argentina, C1122AAF
- Halitus Instituto Medico S.A. - Dermatologia y Estetica
-
Rosario, Argentina, S2000DBS
- Instituto De Especialidades De La Salud SRL
-
San Fernando, Argentina, B1646
- MR Medicina Reumatologica
-
San Miguel de Tucumán, Argentina, T4000
- Instituto de Investigaciones Medicas Tucuman
-
-
-
-
-
Clayton, Australia, 3168
- Monash Medical Centre
-
Coorparoo, Australia, 4151
- Cornerstone Dermatology
-
Greenslopes, Australia, 4120
- Veracity Clinical Research
-
Kogarah, Australia, 2217
- Premier Specialists
-
Melbourne, Australia, 3004
- The Alfred Hospital
-
Melbourne, Australia, 3050
- Royal Melbourne Hospital
-
Mitcham, Australia, 3132
- ISHI dermatology
-
Westmead, Australia, 2145
- Westmead Hospital
-
-
-
-
-
Brussels, Belgia, 1090
- UZ Brussel
-
Ghent, Belgia, 9000
- Ghent University Hospital
-
Ghent, Belgia, 9000
- AZ St. Lucas
-
Leuven, Belgia, 3000
- Universitair Ziekenhuis Leuven
-
Liège, Belgia, 4000
- Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
-
Maldegem, Belgia, 9990
- Dermatologie Maldegem
-
-
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1E 1V4
- Skincare Studio Inc Dermatology Clinical Trials
-
-
Ontario
-
Ajax, Ontario, Canada, L1S7K8
- CCA Medical Research Corporation
-
Barrie, Ontario, Canada, L4M 7G1
- SimcoDerm Medical and Surgical Dermatology Centre
-
Hamilton, Ontario, Canada, L8N 1Y2
- Dermatrials Research
-
London, Ontario, Canada, N6A 5R9
- Lovegrove Dermatology
-
Markham, Ontario, Canada, L3P 1X3
- Lynderm Research Inc.
-
Waterloo, Ontario, Canada, N2J 1C4
- Alliance Clinical Trials
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 2V1
- Innovaderm Research Inc.
-
Québec, Quebec, Canada, G1W 4R4
- The Centre de recherche Saint-Louis
-
-
-
-
-
Aalborg, Danmark, 9100
- Aalborg Sygehus Syd
-
Aarhus, Danmark, 8200
- Aarhus University Hospital
-
Hellerup, Danmark, 2900
- Gentofte Hospital
-
København NV, Danmark, 2400
- Bispebjerg Hospital
-
Odense, Danmark, 5000
- Odense University Hospital
-
Roskilde, Danmark, 4000
- Sjællands University hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35244
- Cahaba Research Inc
-
-
California
-
Encinitas, California, Forente stater, 92024
- California Dermatology & Clinical Research Institute
-
Encino, California, Forente stater, 91436
- T Joseph Raoof Md Inc
-
Fountain Valley, California, Forente stater, 92708
- First OC Dermatology
-
Oceanside, California, Forente stater, 92056
- Dermatologist Medical Group of North County, Inc.
-
Rocklin, California, Forente stater, 95765
- NorCal Clinical Research
-
Sacramento, California, Forente stater, 95815
- Integrative Skin Science and Research
-
San Diego, California, Forente stater, 92103
- MedDerm Associates
-
Santa Ana, California, Forente stater, 92701
- Southern California Dermatology
-
Sylmar, California, Forente stater, 91342
- Olive View-UCLA Education & Research Institute
-
-
Connecticut
-
Farmington, Connecticut, Forente stater, 06030
- University of Conn Health Center
-
-
Florida
-
Miami, Florida, Forente stater, 33155
- Bioclinical Research Alliance Inc.
-
Miami, Florida, Forente stater, 33126
- Driven Research LLC
-
Ocala, Florida, Forente stater, 34470
- Renstar Medical Research
-
Tampa, Florida, Forente stater, 33613
- Forcare Clinical Research Inc
-
-
Georgia
-
Alpharetta, Georgia, Forente stater, 30022
- Hamilton Research LLC
-
-
Illinois
-
Skokie, Illinois, Forente stater, 60076
- Northshore Medical Group
-
-
Indiana
-
Plainfield, Indiana, Forente stater, 46168
- Indiana Clinical Trial Center
-
-
Iowa
-
Iowa City, Iowa, Forente stater, 52242
- University of Iowa
-
-
Kentucky
-
Bowling Green, Kentucky, Forente stater, 42104
- Equity Medical
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02111
- Tufts Medical Center
-
Brighton, Massachusetts, Forente stater, 02135
- Metro Boston Clinical Partners
-
-
Michigan
-
Caledonia, Michigan, Forente stater, 49316
- The Derm Institute of West Michigan
-
Detroit, Michigan, Forente stater, 48202
- Henry Ford Hospital
-
Fort Gratiot, Michigan, Forente stater, 48059
- Hamzavi Dermatology
-
Troy, Michigan, Forente stater, 48084
- Somerset Skin Centre
-
-
Minnesota
-
New Brighton, Minnesota, Forente stater, 55112
- Minnesota Clinical Study Center
-
-
Missouri
-
Kirksville, Missouri, Forente stater, 63501
- Cleaver Dermatology
-
Saint Joseph, Missouri, Forente stater, 64506
- MediSearch Clinical Trials
-
-
New York
-
New York, New York, Forente stater, 10075
- Sadick Research Group
-
New York, New York, Forente stater, 10028
- Mount Sinai Doctors Dermatology
-
-
North Carolina
-
Wilmington, North Carolina, Forente stater, 28405
- Wilmington Dermatology Center
-
-
Ohio
-
Boardman, Ohio, Forente stater, 44512
- Optima Research
-
Mayfield Heights, Ohio, Forente stater, 44124
- Apex Dermatology Mayfield Heights
-
-
Oregon
-
Portland, Oregon, Forente stater, 97210
- Oregon Dermatology and Research Center
-
Portland, Oregon, Forente stater, 97201
- Oregon Medical Research Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19114
- Clinical Research Philadelphia
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- UPMC Department of Dermatology
-
-
South Dakota
-
Rapid City, South Dakota, Forente stater, 57702
- Health Concepts
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37211
- Advanced Research Experts PLLC
-
-
Texas
-
Arlington, Texas, Forente stater, 76011
- Arlington Research Center, Inc.
-
Dallas, Texas, Forente stater, 75231
- Modern Research Associates PLLC
-
Houston, Texas, Forente stater, 77004
- Center for Clinical Studies 1
-
San Antonio, Texas, Forente stater, 78218
- Texas Dermatology and Laser Specialists
-
San Antonio, Texas, Forente stater, 78213
- Progressive Clinical Research
-
Webster, Texas, Forente stater, 77598
- Center for Clinical Studies
-
-
Utah
-
West Valley City, Utah, Forente stater, 84120
- Kalo Clinical Research
-
-
Washington
-
Mill Creek, Washington, Forente stater, 98012
- Frontier Derm Partners CRO, LLC
-
-
-
-
-
Bialystok, Polen, 15 375
- Specderm Poznanska sp j
-
Bialystok, Polen, 15-351
- Osteo-Medic s.c A. Racewicz, J Supronik
-
Elblag, Polen, 82 300
- Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska
-
Katowice, Polen, 40 568
- Care Clinic Sp z o o
-
Krakow, Polen, 30 002
- Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna
-
Lodz, Polen, 90-265
- Dermed Centrum Medyczne Sp z o o
-
Olsztyn, Polen, 10-117
- Etyka Osrodek Badan Klinicznych
-
Poznan, Polen, 60 529
- SOLUMED Centrum Medyczne
-
Skierniewice, Polen, 96 100
- Velocity Nova Sp z o o
-
Warsaw, Polen, 02 661
- Magdalena Opadczuk Carpe Diem Centrum Medycyny Estetycznej
-
Warsaw, Polen, 02 953
- Klinika Ambroziak Dermatologia
-
Wroclaw, Polen, 52 416
- Centrum Medyczne Oporow
-
Wroclaw, Polen, 51 685
- WroMedica I Bielicka A Strzalkowska s c
-
-
-
-
-
Guimarães, Portugal, 4835 044
- Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes
-
Leiria, Portugal, 2410 197
- Unidade Local De Saude Da Regiao De Leiria Epe
-
Lisbon, Portugal, 1169 050
- Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
-
Lisbon, Portugal, 1998 018
- Hosp. Cuf Descobertas
-
Porto, Portugal, 4099 001
- Ulssa Hosp. Santo Antonio
-
-
-
-
-
Alicante, Spania, 03010
- Hosp. Gral. Univ. Dr. Balmis
-
Barakaldo, Spania, 48902
- Hosp. Univ. de Cruces
-
Barcelona, Spania, 08036
- Hosp. Clinic de Barcelona
-
Granada, Spania, 18016
- Hosp. Univ. San Cecilio
-
Madrid, Spania, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, Spania, 28006
- Hosp. Univ. de La Princesa
-
Madrid, Spania, 28002
- Grupo Dermatologico Y Estetico Pedro Jaen
-
Manises, Spania, 46940
- Hosp. de Manises
-
Santiago Compostela, Spania, 15706
- Hosp. Clinico Univ. de Santiago
-
Seville, Spania, 41009
- Hosp. Virgen Macarena
-
Seville, Spania, 41014
- Hosp. Ntra. Sra. de Valme
-
Valencia, Spania, 46026
- Hosp. Univ. I Politecni La Fe
-
Villajoyosa, Spania, 03570
- Hosp. de La Marina Baixa
-
Zaragoza, Spania, 50009
- Hosp. Clinico Univ. Lozano Blesa
-
Zaragoza, Spania, 50009
- Hosp. Univ. Miguel Servet
-
-
-
-
-
Dudley, Storbritannia, DY1 2HQ
- Dudley Group NHS Foundation Trust
-
Harrow, Storbritannia, HA1 3UJ
- London North West University Healthcare NHS Trust
-
Kings Lynn, Storbritannia, PE30 4ET
- The Queen Elizabeth Hospital NHS Foundation Trust
-
London, Storbritannia, SE1 9RT
- Guys and St Thomas NHS Foundation Trust
-
Reading, Storbritannia, RG1 5AN
- Royal Berkshire Hospital
-
Salford, Storbritannia, M6 8HD
- Salford Royal Hospital
-
Southampton, Storbritannia, So166yd
- University Hospital Southampton
-
Wakefield, Storbritannia, WF1 4DG
- Mid Yorkshire Hospital NHS Trust- Pinderfields Hospital
-
-
-
-
-
Augsburg, Tyskland, 86179
- Klinikum Augsburg
-
Bad Bentheim, Tyskland, 48455
- Fachklinik Bad Bentheim
-
Berlin, Tyskland, 10789
- ISA - Interdisciplinary Study Association GmbH
-
Bonn, Tyskland, 53127
- Universitatsklinikum Bonn
-
Bramsche, Tyskland, 49565
- Studienzentrum an der Hase GbR
-
Darmstadt, Tyskland, 64283
- Rosenpark Research GmbH
-
Dresden, Tyskland, 01307
- Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden
-
Friedrichshafen, Tyskland, 88045
- Derma-Study-Center Friedrichshafen GmbH
-
Kiel, Tyskland, 24105
- Universitaetsklinikum Schleswig Holstein Campus Kiel
-
Langenau, Tyskland, 89129
- Studienzentrum Dr Schwarz Germany
-
Mahlow, Tyskland, 15831
- Dermatologie Mahlow
-
Mainz, Tyskland, 55128
- Gemeinschaftspraxis Dres. Quist
-
Münster, Tyskland, 48149
- Universitaetsklinikum Muenster
-
Witten, Tyskland, 58453
- Hautarztpraxis
-
-
-
-
-
Budapest, Ungarn, 1036
- Obudai Egeszsegugyi Centrum Kft
-
Budapest, Ungarn, 1152
- Uno Medical Trials Ltd.
-
Debrecen, Ungarn, 4032
- Debreceni Egyetem Klinikai Kozpont
-
Debrecen, Ungarn, 4031
- Derma-B Kft
-
Gyula, Ungarn, 5700
- Synexus Magyarorszag Kft
-
Gyöngyös, Ungarn, 3200
- Gyongyosi Bugat Pal Korhaz
-
Hódmezővásárhely, Ungarn, 6800
- Porcika Klinika - Vasarhelyi Sarkanyfu Kft.
-
Kaposvár, Ungarn, 7400
- Somogy Varmegyei Kaposi Mor Oktato Korhaz
-
Kecskemét, Ungarn, 6000
- Bacs-kiskun Megyei Korhaz
-
Szolnok, Ungarn, 5000
- Allergo-Derm Bakos Kft.
-
Veszprém, Ungarn, 8200
- Medmare Egeszsegugyi Es Szolgaltato Bt.
-
-
-
-
-
Feldkirch, Østerrike, 6800
- LKH Feldkirch
-
Linz, Østerrike, 4020
- Kepler Universitatsklinikum GmbH
-
Sankt Pölten, Østerrike, 3100
- Universtitatsklinikum St Poelten
-
Vienna, Østerrike, 1090
- Allgemeines Krankenhaus der Stadt Wien
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
- Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
- Total psoriasis area and severity index (PASI) >=12 at screening and baseline
- Total investigator global assessment (IGA) >=3 at screening and baseline
- Candidate for phototherapy or systemic treatment for plaque psoriasis
Exclusion Criteria:
- Nonplaque form of psoriasis (for example [e.g.], erythrodermic, guttate, or pustular)
- Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
- Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
- Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
- Transplanted organ (with exception of a corneal transplant greater than [>] 12 weeks before the first administration of study intervention)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Arm 1: JNJ 77242113
Participants will receive JNJ-77242113 once daily from Week 0 through Week 104. All participant will receive ustekinumab matching placebo at Week 0, 4 and 16 to maintain the blind. |
JNJ-77242113 will be administered orally. Matching placebo will be administered subcutaneously. |
|
Placebo komparator: Arm 2: Placebo
Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for ustekinumab at Week 0, 4 and 16 and JNJ-77242113 from Week 16 through Week 104. |
JNJ-77242113 will be administered orally. Matching placebo will be administered subcutaneously. Matching placebo will be administered orally. |
|
Aktiv komparator: Arm 3: Ustekinumab
Participants will receive Ustekinumab at Week 0, Week 4, and Week 16 followed by JNJ-77242113 once daily from Week 28 through Week 104. Participants will receive both Ustekinumab and placebo for JNJ-77242113 to maintain the blind through Week 28. |
JNJ-77242113 will be administered orally. Matching placebo will be administered orally. Ustekinumab will be administered subcutaneously.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater than or Equal to (>=) 2 Grade Improvement from Baseline at Week 16
Tidsramme: Week 16
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Tidsramme: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score. |
Week 16
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 75 Response at Week 16
Tidsramme: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents participants achieving at least a 75 percent improvement from baseline in the PASI score. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Tidsramme: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with IGA Score of 0 at Week 16
Tidsramme: Week 16
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 28
Tidsramme: Week 28
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 28
Tidsramme: Week 28
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 28
Tidsramme: Week 28
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score. |
Week 28
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 16
Tidsramme: Week 16
|
PSSD includes patient-reported outcome (PRO) questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 16
Tidsramme: Week 16
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 16
|
|
Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: Up to Week 108
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. SAE is any untoward medical occurrence that results in: death, is life-threatening, requires in-patient hospitalization/prolongs existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of infectious agent via medicinal product & is medically important. |
Up to Week 108
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Sign Score of 0 at Week 16
Tidsramme: Week 16
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. This PRO includes 11 items in total, with 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). A 0 to 10 numerical rating scale for severity is used to rank the psoriasis sign score. A higher score indicates more severe disease. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Change from Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16
Tidsramme: Baseline up to Week 16
|
DLQI will be utilized in the adult population and is a dermatology specific health related quality of life (HRQoL) instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Baseline up to Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 16
Tidsramme: Week 16
|
DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10 item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Change from Baseline in Body Surface Area (BSA) Score at Week 16
Tidsramme: Baseline up to Week 16
|
BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (that is., plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA. |
Baseline up to Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 28
Tidsramme: Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Sign Score at Week 28
Tidsramme: Baseline up to Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Baseline up to Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Symptom Score at Week 28
Tidsramme: Baseline up to Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Baseline up to Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Sign Score of 0 at Week 28
Tidsramme: Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 28
Tidsramme: Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in DLQI Score at Week 28
Tidsramme: Baseline up to Week 28
|
DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Baseline up to Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 28
Tidsramme: Week 28
|
DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL. It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in BSA Score at Week 16
Tidsramme: Baseline up to Week 16
|
BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (ie, plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA. |
Baseline up to Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 16
Tidsramme: Week 16
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 16
Tidsramme: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score. |
Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Tidsramme: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score. |
Week 16
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 77242113PSO3006
- 77242113PSO3006 (Annen identifikator: Janssen Research & Development, LLC)
- 2024-515706-77-00 (Registeridentifikator: EUCT number)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .